Tag Archives: Kadmon Holdings

Analysts Have Conflicting Sentiments on These Healthcare Companies: Kadmon Holdings (NASDAQ: KDMN), Lineage Cell Therapeutics (NYSE MKT: LCTX) and Ascendis Pharma (NASDAQ: ASND)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kadmon Holdings (KDMN – Research Report), Lineage Cell Therapeutics (LCTX – Research Report) and Ascendis Pharma (ASND – Research Report). TipRanks has tracked

H.C. Wainwright Maintains Their Buy Rating on Kadmon Holdings (KDMN)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Kadmon Holdings (KDMN – Research Report), with a price target of $20.00. The company’s shares closed last Thursday at $4.14. According to TipRanks.com, Fein is

Kadmon Holdings (KDMN) Received its Third Buy in a Row

After Jefferies and Mizuho Securities gave Kadmon Holdings (NASDAQ: KDMN) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Mark Breidenbach maintained a Buy rating on Kadmon Holdings today and set a price target

H.C. Wainwright Believes Kadmon Holdings (NASDAQ: KDMN) Won’t Stop Here

In a report issued on February 2, Andrew Fein from H.C. Wainwright maintained a Buy rating on Kadmon Holdings (KDMN – Research Report), with a price target of $25.00. The company’s shares closed last Tuesday at $5.47, close to its

Kadmon Holdings (KDMN) Gets a Buy Rating from H.C. Wainwright

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Kadmon Holdings (KDMN – Research Report), with a price target of $25.00. The company’s shares closed last Friday at $3.19. According to TipRanks.com, Fein is

Kadmon Holdings (KDMN) Receives a Buy from Raymond James

Raymond James analyst Steven Seedhouse maintained a Buy rating on Kadmon Holdings (KDMN – Research Report) yesterday. The company’s shares closed last Wednesday at $3.92. According to TipRanks.com, Seedhouse is a 5-star analyst with an average return of 17.0% and